IDH2 and oligodendroglioma: A novel TERT-targeting therapy [44, 45] would be expected to specifically target IDH-wildtype GBM including primary brain tumor initiating cells and 1p/19q-codeleted oligodendroglioma which have characteristically possessed hotspot mutations in the TERT promoter region [5, 33].